Literature DB >> 18186095

Carbohydrate-mediated targeting of antigen to dendritic cells leads to enhanced presentation of antigen to T cells.

Eddie W Adams1, Daniel M Ratner, Peter H Seeberger, Nir Hacohen.   

Abstract

The unique therapeutic value of dendritic cells (DCs) for the treatment of allergy, autoimmunity and transplant rejection is predicated upon our ability to selectively deliver antigens, drugs or nucleic acids to DCs in vivo. Here we describe a method for delivering whole protein antigens to DCs based on carbohydrate-mediated targeting of DC-expressed lectins. A series of synthetic carbohydrates was chemically-coupled to a model antigen, ovalbumin (OVA), and each conjugate was evaluated for its ability to increase the efficiency of antigen presentation by murine DCs to OVA-specific T cells (CD4(+) and CD8(+)). In vitro data are presented that demonstrate that carbohydrate modification of OVA leads to a 50-fold enhancement of presentation of antigenic peptide to CD4(+) T cells. A tenfold enhancement is observed for CD8(+) T cells; this indicates that the targeted lectin(s) can mediate cross-presentation of antigens on MHC class I. Our data indicate that the observed enhancements in antigen presentation are unique to OVA that is conjugated to complex oligosaccharides, such as a high-mannose nonasaccharide, but not to monosaccharides. Taken together, our data suggest that a DC targeting strategy that is based upon carbohydrate-lectin interactions is a promising approach for enhancing antigen presentation via class I and class II molecules.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18186095      PMCID: PMC2700842          DOI: 10.1002/cbic.200700310

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  29 in total

Review 1.  Get into the groove! Targeting antigens to MHC class II.

Authors:  J van Bergen; F Ossendorp; R Jordens; A M Mommaas; J W Drijfhout; F Koning
Journal:  Immunol Rev       Date:  1999-12       Impact factor: 12.988

Review 2.  Dendritic cell subsets and the regulation of Th1/Th2 responses.

Authors:  R Maldonado-López; M Moser
Journal:  Semin Immunol       Date:  2001-10       Impact factor: 11.130

Review 3.  Endogenous lectins as targets for drug delivery.

Authors:  N Yamazaki; S Kojima; N V Bovin; S André; S Gabius; H J Gabius
Journal:  Adv Drug Deliv Rev       Date:  2000-09-30       Impact factor: 15.470

4.  A schistosome-expressed immunomodulatory glycoconjugate expands peritoneal Gr1(+) macrophages that suppress naive CD4(+) T cell proliferation via an IFN-gamma and nitric oxide-dependent mechanism.

Authors:  O Atochina; T Daly-Engel; D Piskorska; E McGuire; D A Harn
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

5.  Automated solid-phase synthesis of oligosaccharides.

Authors:  O J Plante; E R Palmacci; P H Seeberger
Journal:  Science       Date:  2001-02-01       Impact factor: 47.728

6.  Five mouse homologues of the human dendritic cell C-type lectin, DC-SIGN.

Authors:  C G Park; K Takahara; E Umemoto; Y Yashima; K Matsubara; Y Matsuda; B E Clausen; K Inaba; R M Steinman
Journal:  Int Immunol       Date:  2001-10       Impact factor: 4.823

7.  Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand.

Authors:  N Mach; S Gillessen; S B Wilson; C Sheehan; M Mihm; G Dranoff
Journal:  Cancer Res       Date:  2000-06-15       Impact factor: 12.701

8.  Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo.

Authors:  D Hawiger; K Inaba; Y Dorsett; M Guo; K Mahnke; M Rivera; J V Ravetch; R M Steinman; M C Nussenzweig
Journal:  J Exp Med       Date:  2001-09-17       Impact factor: 14.307

9.  The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments.

Authors:  K Mahnke; M Guo; S Lee; H Sepulveda; S L Swain; M Nussenzweig; R M Steinman
Journal:  J Cell Biol       Date:  2000-10-30       Impact factor: 10.539

10.  Functional comparison of mouse CIRE/mouse DC-SIGN and human DC-SIGN.

Authors:  Irina Caminschi; Alexandra J Corbett; Corina Zahra; Mireille Lahoud; Karen M Lucas; Mariam Sofi; David Vremec; Thomas Gramberg; Stefan Pöhlmann; Joan Curtis; Emanuela Handman; Serani L H van Dommelen; Peter Fleming; Mariapia A Degli-Esposti; Ken Shortman; Mark D Wright
Journal:  Int Immunol       Date:  2006-03-28       Impact factor: 4.823

View more
  26 in total

1.  Carbohydrate-functionalized nanovaccines preserve HIV-1 antigen stability and activate antigen presenting cells.

Authors:  J E Vela Ramirez; R Roychoudhury; H H Habte; M W Cho; N L B Pohl; B Narasimhan
Journal:  J Biomater Sci Polym Ed       Date:  2014-07-28       Impact factor: 3.517

2.  Surface-modified P(HEMA-co-MAA) nanogel carriers for oral vaccine delivery: design, characterization, and in vitro targeting evaluation.

Authors:  Matilde Durán-Lobato; Brenda Carrillo-Conde; Yasmine Khairandish; Nicholas A Peppas
Journal:  Biomacromolecules       Date:  2014-07-02       Impact factor: 6.988

3.  Immunogenicity of protein therapeutics: The key causes, consequences and challenges.

Authors:  Matthew P Baker; Helen M Reynolds; Brooke Lumicisi; Christine J Bryson
Journal:  Self Nonself       Date:  2010-10

4.  Pathogen-derived oligosaccharides improve innate immune response to intracellular parasite infection.

Authors:  Alex Osanya; Eun-Ho Song; Kyle Metz; Raeann M Shimak; Paola Mercedes Boggiatto; Elise Huffman; Charles Johnson; Jesse M Hostetter; Nicola L B Pohl; Christine A Petersen
Journal:  Am J Pathol       Date:  2011-07-16       Impact factor: 4.307

5.  Targeting CpG Adjuvant to Lymph Node via Dextran Conjugate Enhances Antitumor Immunotherapy.

Authors:  Weidong Zhang; Myunggi An; Jingchao Xi; Haipeng Liu
Journal:  Bioconjug Chem       Date:  2017-07-06       Impact factor: 4.774

6.  N-glycan targeted gene delivery to the dendritic cell SIGN receptor.

Authors:  Kevin Anderson; Christian Fernandez; Kevin G Rice
Journal:  Bioconjug Chem       Date:  2010-08-18       Impact factor: 4.774

Review 7.  Immunogenicity Risk Assessment for an Engineered Human Cytokine Analogue Expressed in Different Cell Substrates.

Authors:  Paul Chamberlain; Bonita Rup
Journal:  AAPS J       Date:  2020-04-14       Impact factor: 4.009

Review 8.  Recent advancements in cytotoxic T lymphocyte generation methods using carbohydrate-coated liposomes.

Authors:  Yuzuru Ikehara; Masahiro Yamanaka; Takashi Yamaguchi
Journal:  J Biomed Biotechnol       Date:  2010-06-17

9.  Molecular factors in dendritic cell responses to adsorbed glycoconjugates.

Authors:  Nathan A Hotaling; Richard D Cummings; Daniel M Ratner; Julia E Babensee
Journal:  Biomaterials       Date:  2014-04-16       Impact factor: 12.479

10.  Liposomes and nanotechnology in drug development: focus on oncotargets.

Authors:  Tomohiro Kozako; Naomichi Arima; Makoto Yoshimitsu; Shin-Ichro Honda; Shinji Soeda
Journal:  Int J Nanomedicine       Date:  2012-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.